These data validate previous PKC inhibitor analyses in UM cell lines [8], confirming that although PKC inhibition suppressed MAPK signalling and tumour cell proliferation, this was not sufficient to produce meaningful clinical benefits in patients with advanced UM. The gene discussed is PRRT2; the disease is neoplasm.